Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension

• Published in: Hypertension (Dallas, Tex. 1979) Vol. 69; no. 1; pp. 32 - 41
• Main Authors: Wang, Tzung-Dau, Tan, Ru-San, Lee, Hae-Young, Ihm, Sang-Hyun, Rhee, Moo-Yong, Tomlinson, Brian, Pal, Parasar, Yang, Fan, Hirschhorn, Elizabeth, Prescott, Margaret F., Hinder, Markus, Langenickel, Thomas H.
• Format: Journal Article
• Language: English
• Published: United States American Heart Association, Inc 01.01.2017
• Subjects: Aminobutyrates - administration & dosage; Aminobutyrates - pharmacokinetics; Angiotensin Receptor Antagonists - administration & dosage; Angiotensin Receptor Antagonists - pharmacokinetics; Blood Pressure - drug effects; Cross-Over Studies; Diuresis - drug effects; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Humans; Hypertension - drug therapy; Hypertension - metabolism; Hypertension - physiopathology; Male; Middle Aged; Natriuresis - drug effects; Natriuretic Peptide, Brain - blood; Peptide Fragments - blood; Sodium Chloride, Dietary - pharmacology; Tetrazoles - administration & dosage; Tetrazoles - pharmacokinetics; Time Factors; blood pressure; natriuresis; LCZ696; diuresis; salt-sensitive hypertension
• ISSN: 0194-911X; 1524-4563; 1524-4563
• DOI: 10.1161/HYPERTENSIONAHA.116.08484

Salt-sensitive hypertension (SSH) is characterized by impaired sodium excretion and subnormal vasodilatory response to salt loading. Sacubitril/valsartan (LCZ696) was hypothesized to increase natriuresis and diuresis and result in superior blood pressure control compared with valsartan in Asian patients with SSH. In this randomized, double-blind, crossover study, 72 patients with SSH received sacubitril/valsartan 400 mg and valsartan 320 mg once daily for 4 weeks each. SSH was diagnosed if the mean arterial pressure increased by ≥10% when patients switched from low (50 mmol/d) to high (320 mmol/d) sodium diet. The primary outcome was cumulative 6- and 24-hour sodium excretion after first dose administration. Compared with valsartan, sacubitril/valsartan was associated with a significant increase in natriuresis (adjusted treatment difference24.5 mmol/6 hours, 50.3 mmol/24 hours, both P<0.001) and diuresis (adjusted treatment difference291.2 mL/6 hours, P<0.001; 356.4 mL/24 hours, P=0.002) on day 1, but not on day 28, and greater reductions in office and ambulatory blood pressure on day 28. Despite morning dosing of both drugs, ambulatory blood pressure reductions were more pronounced at nighttime than at daytime or the 24-hour average. Compared with valsartan, sacubitril/valsartan significantly reduced N-terminal pro B-type natriuretic peptide levels on day 28 (adjusted treatment difference−20%; P=0.001). Sacubitril/valsartan and valsartan were safe and well tolerated with no significant changes in body weight or serum sodium and potassium levels with either treatments. In conclusion, sacubitril/valsartan compared with valsartan was associated with short-term increases in natriuresis and diuresis, superior office and ambulatory blood pressure control, and significantly reduced N-terminal pro B-type natriuretic peptide levels in Asian patients with SSH. CLINICAL TRIAL REGISTRATION—URLhttp://www.clinicaltrials.gov. Unique identifierNCT01681576.